Scientists have concluded that the Meningitis B vaccine provides no protection against gonorrhoea infections, contradicting earlier hopes that the shot could serve a dual purpose in preventing both diseases.
Researchers found that while the MenB vaccine effectively protects against meningococcal disease, it fails to prevent gonorrhoea caused by Neisseria gonorrhoeae, a related but distinct bacterial pathogen. The bacteria share structural similarities, which initially prompted health authorities in some regions to recommend MenB vaccination as part of gonorrhoea prevention strategies for high-risk men.
The study undermines previous research suggesting cross-protection between the vaccines. Public health officials had promoted MenB shots to men who have sex with men and other at-risk groups partly based on the theory that immunity to the meningococcus bacterium might extend to the gonorrhoea pathogen.
Gonorrhoea remains a major public health concern globally. The infection has developed significant antibiotic resistance, creating treatment challenges and limiting prevention options. Health agencies have sought multiple intervention strategies, including vaccines, to curb transmission rates.
The findings redirect focus back to developing specific gonorrhoea vaccines rather than relying on existing meningococcal formulations. Researchers continue working on purpose-built shots targeting the gonorrhoea bacterium directly.
Health authorities will likely adjust their messaging around MenB vaccination, clarifying that while the shot protects against meningitis, men seeking gonorrhoea prevention must rely on other methods including regular testing, condom use, and partner notification. The research highlights the complexity of vaccine cross-reactivity and the risks of assuming protection extends across related pathogens without robust clinical evidence.